NetraMark Achieves Major FDA Milestone

TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced the completion of its Critical Path Innovation Meeting (CPIM) with the U.S. Food and Drug Administration (FDA). During this scientific exchange, FDA provided feedback on NetraAI—NetraMark's explainable ...